<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164655</url>
  </required_header>
  <id_info>
    <org_study_id>UCGI 30 - PRODIGE 53 SULTAN</org_study_id>
    <secondary_id>2016-001493-15</secondary_id>
    <nct_id>NCT03164655</nct_id>
  </id_info>
  <brief_title>Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network</brief_title>
  <acronym>SULTAN</acronym>
  <official_title>A Randomized Phase II Study Comparing Treatment Intensification With CIAH Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      National trial, multicenter, randomized, phase II comparing treatment intensification with&#xD;
      hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic&#xD;
      chemotherapy alone in patients with liver-only colorectal metastases (CRLM) considered still&#xD;
      non resectable after at least two months of systemic induction chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      to compare the efficacy of CT intensification combining hepatic arterial infusion(HAI)&#xD;
      oxaliplatin plus IV FOLFIRI plus targeted therapy (anti-epidermal growth factor receptor&#xD;
      (EGFR) or bevacizumab) to conventional systemic CT alone plus targeted therapy (anti-EGFR or&#xD;
      antiangiogenic antibody), in patients with liver-only CRLM not amenable to curative-intent&#xD;
      resection (and/or ablation) after systemic induction CT in terms of conversion to complete&#xD;
      (R0 R1) resection (or ablation) rate (CRR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    -  insufficient patient enrollment&#xD;
&#xD;
      -  cessation of commercialization in EU of intra hepatic catheter by Bbraun Company&#xD;
  </why_stopped>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM</measure>
    <time_frame>6 months</time_frame>
    <description>Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM confirmed by a systematic review of the surgical and pathological report by an independent committee blind to the treatment received</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>HAI oxaliplatin combined with I.V. FOLFIRI + target therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAI oxaliplatin 100 mg/m² on D1&#xD;
I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT&#xD;
modified FOLFIRI regimen without fluorouracil bolus&#xD;
I.V. irinotecan 180 mg/m² D1&#xD;
I.V. bolus 5-Fluorouracil (5-FU): 0&#xD;
I.V. leucovorin 400 mg/m² in 2 hours D1&#xD;
I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional systemic CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Response to systemic induction CT&#xD;
Toxicity and duration of the systemic induction CT&#xD;
RAS status&#xD;
Current guidelines/standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil</intervention_name>
    <description>Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h</description>
    <arm_group_label>HAI oxaliplatin combined with I.V. FOLFIRI + target therapy</arm_group_label>
    <arm_group_label>conventional systemic CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed colorectal cancer (CRC), and radiologic or histologic proof&#xD;
             of CRLM not amenable to a curative intent-treatment.&#xD;
&#xD;
          2. At least two months of prior induction systemic CT with oxaliplatin and/or irinotecan&#xD;
             combined with a fluoropyrimidine combined or not to a targeted therapy (e.g.,&#xD;
             anti-EGFR or antiangiogenic antibody) for metastatic disease (patients ending their&#xD;
             adjuvant chemotherapy after primary tumor resection since more than 6 months should&#xD;
             also have received first-line chemotherapy for metastatic disease). Further systemic&#xD;
             chemotherapy lines are allowed.&#xD;
&#xD;
          3. Unresectability of the CRLM will be confirmed by a centralized multidisciplinary&#xD;
             expert panel (composed of surgeons, radiologists, interventional radiologists and&#xD;
             medical oncologists). The panel will review the CT scan and MRI of the patients&#xD;
             (weekly web conference). Non-resectability criteria (one of the following criteria):&#xD;
&#xD;
               -  Upfront R0/R1 resection of all CRLM (that leaves at least two adequately perfused&#xD;
                  and drained segments) is not possible&#xD;
&#xD;
               -  and/or metastases in contact with major vessels of the remnant liver which would&#xD;
                  require resection of the vessel for an R0 resection (i.e., tumor involvement of&#xD;
                  main portal right and left portal veins, of the three main hepatic veins, or of&#xD;
                  the retrohepatic vena cava)&#xD;
&#xD;
               -  and/or documented progressive disease on imaging (according to the RECIST v1.1)&#xD;
                  or doubling of serum levels of carcinoembryonic antigen (CEA) or carbohydrate&#xD;
                  antigen 19-9 (CA 19-9) following ≥2 months of induction CT&#xD;
&#xD;
          4. At least one measurable liver metastasis according to the RECIST v1.1&#xD;
&#xD;
          5. Age ≥18 years&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          7. Normal liver function, i.e. bilirubin &lt;1.5 times the upper limit of normal values&#xD;
             (ULN), aminotransferases &lt;5 ULN, alkaline phosphatase &lt;5 ULN&#xD;
&#xD;
          8. International normalized ratio (INR) &lt;1.5 ULN&#xD;
&#xD;
          9. Neutrophils &gt;1500/mm³, platelets &gt;100 000/mm³, hemoglobin &gt;9 g/dL (transfusion&#xD;
             allowed)&#xD;
&#xD;
         10. Calculated creatinine clearance &gt;50 mL/min (Cockcroft and Gault formula)&#xD;
&#xD;
         11. Informed consent signed by the patient or his/her legal representative&#xD;
&#xD;
         12. Patient affiliated to a social security regimen&#xD;
&#xD;
         13. Potentially reproductive patients must agree to use an effective contraceptive method&#xD;
             or practice adequate methods of birth control or practice complete abstinence while on&#xD;
             treatment, and for at least 6 months after the last dose of study drug.&#xD;
&#xD;
         14. Uracilemia &lt;16 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient eligible for curative-intent treatment of CRLM (i.e. resection and/or&#xD;
             thermoablation), according to the local multidisciplinary team and/or the central&#xD;
             review.&#xD;
&#xD;
          2. Definitive anatomical contraindication to complete surgical resection (any of the&#xD;
             following criteria):&#xD;
&#xD;
               -  More than two lesions in all liver segments&#xD;
&#xD;
               -  Bilobar liver metastasis and more than three lesions &gt;3 cm in the hepatic lobe&#xD;
                  the least affected (i.e. the future remnant liver)&#xD;
&#xD;
               -  Bilobar liver metastasis and disease liver extend &gt;50%&#xD;
&#xD;
          3. Extrahepatic tumor disease (except ≤3 lung nodules &lt;10 mm deemed amenable to&#xD;
             curative-intent resection/thermoablation and non-resected primary tumor with no or&#xD;
             mild symptoms)&#xD;
&#xD;
          4. Patient with contraindication for trial drugs (investigators have to refer to drugs&#xD;
             SmPC); contraindication limited to targeted therapy (e.g., anti-EGFR or antiangiogenic&#xD;
             antibody) is not an exclusion criteria&#xD;
&#xD;
          5. Disease progression after FOLFOXIRI/FOLFIRINOX&#xD;
&#xD;
          6. Sensory neuropathy ≥ grade 2 (National Cancer Institute - Common Terminology Criteria&#xD;
             for Adverse Events (NCI-CTCAE) v.4.0)&#xD;
&#xD;
          7. If patients received bevacizumab, following non-inclusion criteria must be respected:&#xD;
&#xD;
               -  Proteinuria &gt;1 g,&#xD;
&#xD;
               -  Gastro-intestinal fistulae or perforation,&#xD;
&#xD;
               -  Hypersensitivity to Chinese hamster ovary cell products or other human&#xD;
                  recombinant antibody,&#xD;
&#xD;
               -  Major surgery in the last 28 days.&#xD;
&#xD;
          8. If patients received panitumumab, following non-inclusion criteria must be respected:&#xD;
&#xD;
               -  Interstitial lung disease,&#xD;
&#xD;
               -  Pulmonary fibrosis.&#xD;
&#xD;
          9. Significant chronic liver disease (resulting in portal hypertension and/or liver&#xD;
             insufficiency)&#xD;
&#xD;
         10. Allergy to contrast media that cannot be managed with standard care&#xD;
&#xD;
         11. Previous organ transplantation, HIV or other immunodeficiency syndromes&#xD;
&#xD;
         12. Concomitant or past history of cancer within 5 years prior to entry into the trial&#xD;
             other than adequately treated basal-cell skin cancer or in situ carcinoma of the&#xD;
             cervix&#xD;
&#xD;
         13. Patients with clinically significant active heart disease or myocardial infarction in&#xD;
             the last 6 months&#xD;
&#xD;
         14. Concomitant medications/comorbidities that may prevent the patient from receiving&#xD;
             study treatments as uncontrolled intercurrent illness (for instance: active infection,&#xD;
             active inflammatory disorders, inflammatory bowel disease, intestinal obstruction,&#xD;
             uncontrolled hypertension systolic &gt;15 and diastolic &gt;9, symptomatic congestive heart&#xD;
             failure…)&#xD;
&#xD;
         15. Ionic disorders as:&#xD;
&#xD;
               -  Kalemia ≥1 x ULN&#xD;
&#xD;
               -  Magnesemia &lt;0.5 mmol/L&#xD;
&#xD;
               -  Calcemia &lt;2 mmol/L&#xD;
&#xD;
         16. Patient with a dihydropyrimidine dehydrogenase (DPD) deficiency; Uracilemia ≥16 ng/ml,&#xD;
             the test should be done for all patients before first 5-FU administration, according&#xD;
             to &quot;agence nationale de sécurité du médicament&quot; (ANSM) communication regarding&#xD;
             recommendation about high risk of no testing DPD in patient before 5-FU administration&#xD;
&#xD;
         17. QT/QTc &gt;450 msec for men and &gt; 470 msec for women&#xD;
&#xD;
         18. Concomitant intake of St. John's wort&#xD;
&#xD;
         19. Patient already included in another clinical trial with an experimental treatment&#xD;
&#xD;
         20. Pregnancy or lactation&#xD;
&#xD;
         21. Patients deprived of liberty or under guardianship&#xD;
&#xD;
         22. Patients unable to undergo medical monitoring test for geographical, social or&#xD;
             psychological reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Boige</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy Villejuif</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ico Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chp Saint Gregoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.</ipd_time_frame>
    <ipd_access_criteria>Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

